A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
Part One Of A Two-Part Interview With NCI Director Harold Varmus
Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
Richard Pazdur’s Comments to ODAC
Department of Defense Offering $16 Million in Cancer Research Grants
Trending Stories
- Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer - Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Pushing for tax cuts, Trump threatens the federal workforce, Medicaid, and cancer research
- “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury